Evidence map›Paper›PMID 34215897›Full record

ArticleSouthern medical journal2021

Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 Pneumonia Who Developed Bradycardia.

Fernando Stancampiano, Mohamed Omer, Dana Harris, Jose Valery, Michael Heckman, Launia White, Claudia Libertin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Southern medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Fernando StancampianoFrom the Division of Community Internal Medicine, the Clinical Research Unit, the Division of Biomedical Statistics and Informatics, and the Division of Infectious Diseases, Mayo Clinic Florida, Jacksonville.
Mohamed OmerFrom the Division of Community Internal Medicine, the Clinical Research Unit, the Division of Biomedical Statistics and Informatics, and the Division of Infectious Diseases, Mayo Clinic Florida, Jacksonville.
Dana HarrisFrom the Division of Community Internal Medicine, the Clinical Research Unit, the Division of Biomedical Statistics and Informatics, and the Division of Infectious Diseases, Mayo Clinic Florida, Jacksonville.
Jose ValeryFrom the Division of Community Internal Medicine, the Clinical Research Unit, the Division of Biomedical Statistics and Informatics, and the Division of Infectious Diseases, Mayo Clinic Florida, Jacksonville.
Michael HeckmanFrom the Division of Community Internal Medicine, the Clinical Research Unit, the Division of Biomedical Statistics and Informatics, and the Division of Infectious Diseases, Mayo Clinic Florida, Jacksonville.
Launia WhiteFrom the Division of Community Internal Medicine, the Clinical Research Unit, the Division of Biomedical Statistics and Informatics, and the Division of Infectious Diseases, Mayo Clinic Florida, Jacksonville.
Claudia LibertinFrom the Division of Community Internal Medicine, the Clinical Research Unit, the Division of Biomedical Statistics and Informatics, and the Division of Infectious Diseases, Mayo Clinic Florida, Jacksonville.
Mayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the clinical characteristics and clinical outcomes of bradycardic patients with coronavirus disease 2019 (COVID-19) pneumonia.

methodsThe electronic medical records of 221 consecutive patients hospitalized for COVID-19 pneumonia between June and September 2020 were retrospectively reviewed. Patient characteristics, electrocardiographic data, and clinical and laboratory information were retrospectively collected. Patients not treated with drugs that blunt chronotropic response (nodal) were analyzed separately.

resultsOnly patients whose heart rate was <60 beats per minute (bpm) (136/221, 61.5%) were included. Serial electrocardiography revealed that most patients (130/137, 97.7%) remained in sinus rhythm. The heart rate was between 50 and 59 bpm in 75% of the patients, while 18.4% were in the 40 to 49 bpm range, and 6.6% were <40 bpm. Medians for development of bradycardia after swab polymerase chain reaction positivity and duration of bradycardia were 41 hours and 5 days, respectively. Bradycardia resolved in 81 patients (59.6%). There were no statistically significant differences in outcomes according to degree of bradycardia (<50 vs 50-59, all

conclusionsSinus bradycardia occurs frequently in patients with severe COVID-19, but the degree of bradycardia does not correlate with clinical outcomes. Lenzilumab may be associated with the resolution of bradycardia.

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBradycardiaCOVID-19ElectrocardiographyFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesYoung AdultAntibodies, Monoclonal, Humanizedlenzilumab

Identifiers

PMID34215897
PMCPMC8231014
OpenAlexW3173726263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.